Viz.ai Overview
Viz.ai provides multidisciplinary care teams with alerts early in the workflow process to connect frontline health care professionals with specialists and facilitate efficient communication and care coordination. Powered by AI, Viz.ai replaces outdated, conventional care practices with a single platform, enabling care teams to save time, reduce leakage, and improve patient quality of life. The company’s products include the Viz LVO and Viz CTP platforms. Both are FDA cleared and commercially available in the United States. The Viz LVO uses artificial intelligence to automatically detect LVO strokes and triage patients directly to a stroke specialist. The Viz CTP uses advanced processing technology to automatically analyze CT perfusion images and generate parametric perfusion color maps.
Cumulative Funding Raised Over Time ($)
$21.0MJul 2018
$92.0MMar 2021
$192.0MMar 2022
$232.0MMar 2023
$239.5MMay 2017
$289.5MOct 2019
Latest News
Viz.ai collects de novo clearance for BMS-backed software to spot hypertrophic cardiomyopathy
Viz.ai Wins Comparably Awards for Best Place to Work for Second Year
growth-positive
Viz.ai Receives $40M Growth Capital Financing
Viz.ai, an AI-powered care coordination platform, has raised $40 million in growth capital financing. The funding will be used to accelerate growth and expand operations. Viz.ais solution connects and activates entire care teams, optimizing care pathways and increasing patient access to life-saving treatments. The company is a pioneer in using AI algorithms and machine learning to speed up diagnosis and care. It currently serves over 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. Viz.ai is backed by Insight Partners, Tiger Global, Kleiner Perkins, Google Ventures, Scale Venture Partners, and Greenoaks Capital Partners.
Investment
growth-positive
Viz.ai Gets FDA Clearance for New RV/LV Ratio Algorithm
The FDA has granted 510(k) clearance for Viz.ais new AI-powered RV/LV ratio algorithm, which facilitates quicker intervention in cases of pulmonary embolism. The algorithm measures heart ventricle diameters and detects potential dilation in the right ventricle, enabling clinicians to determine the ratio of maximum right ventricle diameter to that of the left ventricle. This advance in the Viz.ai Platform allows for timely risk stratification and care in patients with pulmonary embolism, potentially saving lives.
Customers
growth-positive
Viz.ai, Hyperfine partner on new MRI, workflow paradigm
Viz.ai has partnered with Hyperfine to bring MRI to the patients bedside. The partnership aims to enhance the clinical workflow and expedite the clinical teams access to imaging, resulting in better patient outcomes. Viz.ais flagship product, Viz LVO, uses deep learning to provide time-sensitive information about stroke patients to specialists. Hyperfines Swoop is the worlds first MR imaging system that brings imaging to the bedside, reducing wait and transport time for patients. The partnership has the potential to reduce neuroimaging wait times, streamline clinical workflow coordination, and improve patient care.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $289.5M |
| Last funding | $40M |
| Stage | D |
| Rounds | 6 |
| Investors | 16 |
Team Members
4
Employees: 201-500
Web & Social Links
| Website | www.viz.ai |
| Careers | Careers page |
| App Store | App Store |
| Google Play | Google Play |
Locations
Derech Menachem Begin 150, Tel Aviv-Yafo, Israel
San Francisco, CA, United States
Photos & Videos
2 item(s)
Viz.ai Business
Business models
B2B
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesDigital HealthcareClinical WorkflowMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Artificial IntelligenceDeep LearningPlatforms & InterfacesMobileTags (21)
unicorn-2022radiologystrokehealthcare-providersmachine-learningneurologydigital-healthcarescanningartificial-intelligencediagnosticsimagingcritical-caredeep-learningdata-analyticsdoctorsclinicsearly-detectionct-scanmedical-devicesdecision-supportmobile-applicationsGeographic Markets
EuropeUnited StatesViz.ai Financials
$289.5M
Total funding
Undisclosed
Capital raised
$40M
Last funding
D
Funding stage
6
Total rounds
16
Investors
Cumulative Funding Raised Over Time ($)
$21.0MJul 2018
$92.0MMar 2021
$192.0MMar 2022
$232.0MMar 2023
$239.5MMay 2017
$289.5MOct 2019
Private Equity Funding
Undisclosed Round
Mar 2023
$40M
Canadian Imperial Bank of Commerce (Lead)
D Round
Mar 2022
$100M
Tiger Global Management (Lead)
,
Insight Partners, Scale Venture Partners, Sozo Ventures, Google Ventures, Threshold Ventures, Kleiner Perkins, CRV
C Round
Mar 2021
$71M
Insight Partners (Lead)
,
Threshold Ventures, Innovation Endeavors, Scale Venture Partners, CRV, SOSA, Kleiner Perkins
B Round
Oct 2019
$50M
GV, CRV, Kleiner Perkins, Greenoaks Capital
A Round
Jul 2018
$21M
GV, Kleiner Perkins
Seed
May 2017
$7.5M
Innovation Endeavors, AME Cloud Ventures, DHVC (Digital Horizon Capital), Seedcamp
Viz.ai Lifecycle
Cumulative Funding Raised Over Time
$21.0MJul 2018
$92.0MMar 2021
$192.0MMar 2022
$232.0MMar 2023
$239.5MMay 2017
$289.5MOct 2019
All Events
Undisclosed Round
Mar 2023
$40M
Canadian Imperial Bank of Commerce (Lead)
D Round
Mar 2022
$100M
Tiger Global Management (Lead)
,
Insight Partners, Scale Venture Partners, Sozo Ventures, Google Ventures, Threshold Ventures, Kleiner Perkins, CRV
C Round
Mar 2021
$71M
Insight Partners (Lead)
,
Threshold Ventures, Innovation Endeavors, Scale Venture Partners, CRV, SOSA, Kleiner Perkins
B Round
Oct 2019
$50M
GV, CRV, Kleiner Perkins, Greenoaks Capital
A Round
Jul 2018
$21M
GV, Kleiner Perkins
Seed
May 2017
$7.5M
Innovation Endeavors, AME Cloud Ventures, DHVC (Digital Horizon Capital), Seedcamp
Viz.ai News
42 articlesViz.ai collects de novo clearance for BMS-backed software to spot hypertrophic cardiomyopathy
Viz.ai Wins Comparably Awards for Best Place to Work for Second Year
growth-positive
Viz.ai Receives $40M Growth Capital Financing
Viz.ai, an AI-powered care coordination platform, has raised $40 million in growth capital financing. The funding will be used to accelerate growth and expand operations. Viz.ais solution connects and activates entire care teams, optimizing care pathways and increasing patient access to life-saving treatments. The company is a pioneer in using AI algorithms and machine learning to speed up diagnosis and care. It currently serves over 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. Viz.ai is backed by Insight Partners, Tiger Global, Kleiner Perkins, Google Ventures, Scale Venture Partners, and Greenoaks Capital Partners.
Investment
growth-positive
Viz.ai Gets FDA Clearance for New RV/LV Ratio Algorithm
The FDA has granted 510(k) clearance for Viz.ais new AI-powered RV/LV ratio algorithm, which facilitates quicker intervention in cases of pulmonary embolism. The algorithm measures heart ventricle diameters and detects potential dilation in the right ventricle, enabling clinicians to determine the ratio of maximum right ventricle diameter to that of the left ventricle. This advance in the Viz.ai Platform allows for timely risk stratification and care in patients with pulmonary embolism, potentially saving lives.
Customers
growth-positive
Viz.ai, Hyperfine partner on new MRI, workflow paradigm
Viz.ai has partnered with Hyperfine to bring MRI to the patients bedside. The partnership aims to enhance the clinical workflow and expedite the clinical teams access to imaging, resulting in better patient outcomes. Viz.ais flagship product, Viz LVO, uses deep learning to provide time-sensitive information about stroke patients to specialists. Hyperfines Swoop is the worlds first MR imaging system that brings imaging to the bedside, reducing wait and transport time for patients. The partnership has the potential to reduce neuroimaging wait times, streamline clinical workflow coordination, and improve patient care.
Partners
growth-positive
"אנחנו מחברים את בתי החולים לענן - ולטכנולוגיה שמזהה שבץ כמעט בזמן אמת" כלכליסט
Viz.ai, a healthcare startup, has raised $100 million in funding, valuing the company at $1.2 billion. The company uses cloud and AI technology to connect hospitals and analyze scans to detect strokes in real-time. By automating the process, Viz.ai reduces the average time from admission to treatment from two hours to three and a half days. The company currently serves 1,000 hospitals and is able to continuously upgrade its capabilities with the large amount of data it collects. The improved efficiency has led to shorter hospital stays and the ability to treat more patients.
CustomersExpand
growth-positive
The platform analyzing CT scans in real-time and saving lives CTech
Viz.ai, an AI healthcare company, has developed a system that analyzes CT scans to detect strokes and brain hemorrhages. The company has raised a total of $250 million in funding and has a valuation of $1.2 billion. It works with 1,000 hospitals in the U.S. and has received approval from American insurance companies. Viz.ai plans to recruit an additional 200 employees, with half of them based in Israel. The company has also launched an AI-driven life science platform and has signed partnerships with several large life science companies.
CustomersInvestmentExpand
growth-positive
Viz.ai raises $100 million at $1.2 billion valuation to become Israel's newest unicorn CTech
Viz.ai, an Israeli startup that develops an AI-powered disease detection and care coordination platform, has raised a $100 million Series D round at a $1.2 billion valuation. The funding will support the companys growth and expansion. Viz.ais platform is already in use in over 1,000 hospitals, serving millions of patients. The company has also launched AI-driven solutions for various diseases and has signed partnerships with major life science companies. The Series D round was led by Tiger Global and Insight Partners, with participation from existing investors. Viz.ai has raised a total of $250 million to date.
Investment
growth-positive
Viz.ai Receives FDA 510(k) Clearance for Viz Aneurysm
Bayer has teamed up with Calantic and Blackford Analysis to address cerebral aneurysm detection using AI. The AI-powered solution is designed to facilitate population screening and enhanced care management. The partnership aims to bring new AI innovations to the healthcare industry.
Partners
growth-positive
Viz.ai launches two new AI-powered modules for pulmonary embolism and aortic disease - Venous News
Viz.ai has launched AI-powered modules for pulmonary embolism and aortic disease, allowing for faster clinical decision-making and improved care coordination. The modules leverage advanced deep learning to provide time-sensitive information to specialists, improving treatment decisions. Viz.ai has accelerated the time-to-notification of the treatment team by 73% and time-to-treatment by 24%. The launch of these modules expands the reach of Viz.ais platform to a wider range of medical professionals and patients. Viz.ai will be showcasing the modules at VEITHsymposium Booth #317.
CustomersPartners
growth-positive
Medtronic, Viz.ai partner to bring lifesaving AI platform for stroke to EMEA
Medtronic and Viz.ai are extending their partnership to distribute Viz.ais AI software platform for stroke to Europe, the Middle East, and Africa. The AI platform synchronizes stroke care, decreases time to treatment, and improves patient outcomes. Viz.ai recently obtained a CE mark for its software, affirming its conformity with European health and safety legislation. The software uses AI to identify suspected strokes and automatically notify specialists. Medtronic will distribute Viz.ais software services in the USA and CE-mark territories. This partnership aims to bring innovative technology into more markets and improve care coordination.
Partners
growth-positive
זיהוי שבץ מוחי: Viz.ai רוכבת על הזינוק בהלת'-טק ומגייסת 71 מיליון דולר
Viz.ai, an Israeli healthcare technology startup, has raised $71 million in funding led by Insight Partners and Scale Venture Partners. The company has developed a system to streamline the treatment process for stroke cases. Viz.ai has 600 hospitals in the US as customers, including Mount Sinai Hospital in New York. Israeli medtech startups have seen increased demand during the COVID-19 pandemic, and since the beginning of 2021, they have raised a total of $350 million in investments.
Investment
Viz.ai's Viz RECRUIT Software Enables Faster Medical Research
growth-positive
Office Tour: Viz.ai Offices - Tel Aviv
SwitchUP recently designed an office space for Viz.ai, a visual intelligence software company located in Tel Aviv, Israel. The office design accentuates the modern, high-tech nature of Viz.ais work in improving brain scans and life-saving brain surgery. The office features graffiti art, indoor swings, brain-shaped poufs, and nets that mimic brain MRI scans. The kitchen and workroom are designed to encourage collaboration and provide a harmonious mix of open concept and private workstations. The design incorporates elements of greenery and biology throughout the office. Overall, the article has a positive impact on Viz.ais growth by showcasing their innovative and impactful work in the medical field.
Customers
growth-positive
Viz.ai Wins UCSF's 2020 Digital Health Award for Best New Application of A.I.
Viz.ai, an A.I. healthcare company, has won the UCSF Digital Health Award for Best New Application of A.I. The award further validates the real-world benefits of Viz.ais applied artificial intelligence in improving patient outcomes, particularly for stroke patients. The companys flagship product, Viz LVO, uses deep learning algorithms to synchronize stroke care and provide mobile communication and planning tools. Viz.ai has received multiple recognitions as one of the leading AI healthcare companies in the US. The company is backed by investors such as Kleiner Perkins and Google Ventures.
Customers
growth-positive
Viz.ai Granted Medicare New Technology Add-on Payment
Viz.ai has been granted the first New Technology Add-on Payment (NTAP) for artificial intelligence software by CMS. The companys stroke software, Viz LVO, demonstrated a significant reduction in time to treatment and improved clinical outcomes in stroke patients. Viz.ais software has been recognized as a leading AI healthcare solution and has received praise from medical professionals. The NTAP will provide additional reimbursement of up to $1,040 per use for Viz LVO in patients with suspected strokes. This ruling is expected to support the adoption of Viz.ais technology and improve outcomes for stroke patients. Viz.ai is backed by investors such as Kleiner Perkins and Google Ventures.
CustomersInvestment
growth-positive
Israeli Startup Viz.ai Uses AI, Deep Learning To Detect Source Of Stroke In Seconds
Tel Aviv-based medical imaging startup Viz.ai has developed a stroke detection platform that uses artificial intelligence to identify the source of a stroke in seconds. The platform analyzes CT scans to detect early signs of large vessel occlusion strokes and alerts physicians, allowing for quicker treatment and potentially saving patients from long-term brain damage. Viz.ai has raised over $80 million in funding to date and its technology is available in over 300 US hospitals. In addition to stroke detection, Viz.ai offers other products for ischemic and hemorrhagic strokes. The company has also launched a COVID-19 telehealth platform to help hospitals manage patients during the pandemic.
CustomersInvestment
growth-positive
Viz.ai Named to Forbes AI 50 List of Most Promising Artificial Intelligence Companies
Viz.ai has been named to the Forbes Top 50 AI list for its impact in using artificial intelligence to drive change in healthcare. The company is known for improving treatment times in stroke care and is now applying its technology to other aspects of healthcare, including the response to the COVID-19 pandemic. Viz.ai offers products such as Viz COVID-19, Viz CONSULT, and Viz ANALYTICS to improve communication, workflow, and decision making in hospitals. The company aims to improve patient outcomes and ensure the right patient is seen by the right doctor at the right time. Viz.ai is backed by investors including Kleiner Perkins and Google Ventures.
Customers
growth-positive
Saving the lives of stroke victims by streamlining workflow
Israeli tech company Viz.ai provides software that monitors CT-generated images for signs of large vessel occlusion (LVO) strokes and coordinates treatment quickly for stroke patients. The software detects an LVO in under 30 minutes and broadcasts the news to subscribed users, allowing for immediate communication and decision-making among the medical team. Viz.ais software is installed in 300 US hospitals and is being tested in hospitals in Israel. The company has raised $78.5 million in funding and has 85 employees split between Israel and the US. Viz.ai faces competition from other companies using AI to analyze radiological scans, but believes there is enough work to go around.
CustomersPartners
growth-positive
Viz.ai adds new capabilities to their AI stroke platform
Viz.ai has launched the next generation of its synchronized care platform for stroke, incorporating cutting edge artificial intelligence and HIPAA-compliant communication. The platform aims to reduce time to treatment and increase access to endovascular intervention. The new capabilities allow stroke teams to synchronize care from stroke code notification to the post-acute care period, providing quick and relevant clinical and imaging information. The platform has been praised for revolutionizing acute stroke care and transforming the ability to treat cerebrovascular patients. Viz.ai offers enhanced communication capabilities, expanded image viewing and analysis, enhanced security, EHR system integration, and Viz Analytics for stroke service line planning and quality improvement metrics.
CustomersPartners
growth-positive
Huntington Hospital 1st in Los Angeles to Adopt Viz LVO Platform for Artificial Intelligence Powered Stroke Care
Huntington Hospital has partnered with Viz.ai to bring the first FDA-cleared computer-aided triage system for stroke care to the Los Angeles area. The partnership will enhance the hospitals stroke care team through rapid detection and notification of suspected large vessel occlusion (LVO) strokes. Viz.ais applied artificial intelligence solutions will improve access to advanced stroke care and potentially save critical minutes in the triage, diagnosis, and treatment of strokes. The partnership is expected to result in improved outcomes for patients. Huntington Hospital is the first in Los Angeles County to partner with Viz.ai.
PartnersCustomers
growth-positive
Viz.ai launches a range of new AI features
Viz.ai has announced new features at a medical conference, including customisable alerts and a mobile application for stroke teams. The company aims to decrease treatment time and increase the number of patients receiving life-saving treatment. Viz.ais software is built with a security-first mentality and is compliant with federal laws and certifications. The software is now available in over 300 hospitals across the USA.
Customers
growth-positive
https://www.jpost.com/Israel-News/Hillels-Tech-Corner-Time-isnt-just-moneyit-can-be-life-or-death-607910
Viz.ai, a medical imaging company that uses artificial intelligence to optimize emergency treatment, has raised $71 million in series A and B funding rounds. The companys technology can detect signs of a stroke 52 minutes before standard care would have. Viz.ai received FDA approval for its products in the US in February 2018 and has partnered with medical device giant Medtronic to accelerate the adoption of its AI software. The companys software is currently available in more than 300 hospitals across the US.
InvestmentPartners
growth-positive
Viz.ai is Using Machine Learning to Detect the Early Signs of Stroke - Global Shakers
Viz.ai, a healthcare startup specializing in AI, has developed a synchronized healthcare software that uses data-driven AI technology to automatically detect suspected brain abnormalities in CT scans. The platform alerts healthcare professionals within minutes, allowing for faster treatment and improved outcomes for stroke patients. Viz.ais acute ischemic stroke software is currently being used in over 300 hospitals in the US. The company recently raised $50 million in Series B funding, led by Greenoaks, with participation from other investors. The funding will support Viz.ais mission to improve access to lifesaving treatments and deliver high-quality care in a shorter amount of time.
CustomersInvestment
growth-positive
Viz.ai raises $50 million for AI that detects early signs of stroke
Healthcare startup Viz.ai has raised $50 million in a series B funding round led by Greenoaks, with participation from GV and Kleiner Perkins. Viz.ai uses AI to help medical professionals detect early signs of stroke and improve communication and workflow in stroke care. The companys software analyzes brain scans for large vessel occlusions (LVOs) and alerts neurological specialists within minutes. Viz.ais mission is to improve access to lifesaving treatments and achieve significant cost savings for the healthcare system. The funding will enable the company to expand its software into more locations and disease states.
Investment
Viz.ai Named Among Forbes Most Promising AI Companies in America
growth-positive
Medtronic forays further into artificial intelligence
Medtronic has entered into a global distribution agreement with Viz.ai, an AI-powered imaging software company focused on stroke care. Viz.ais software uses AI to quickly determine if a patient has suffered a large-vessel occlusion (LVO) based on a CT scan of the brain, saving valuable time in stroke treatment. The software can alert stroke specialists earlier than the standard of care, potentially saving an average of 52 minutes. The partnership with Medtronic allows for the distribution of Viz.ais software alongside Medtronics stroke hardware products. Viz.ai previously raised $21 million in a Series A funding round led by Kleiner Perkins and participated in by GV.
Partners
growth-positive
Medtronic Partners With Stroke Detection Startup Viz.ai
Medtronic PLC has signed a partnership agreement with stroke detection startup Viz.ai Inc. to distribute Viz.ais technology in the U.S. The financial details of the agreement were not disclosed. Viz.ai develops deep learning and artificial intelligence-powered technology that can analyze brain scans and automatically transfer the information to a doctor for immediate treatment of strokes. Medtronic has previously acquired other Israeli tech companies.
Partners
growth-positive
https://www.jpost.com/Israel-News/With-clock-ticking-Israeli-AI-start-up-slashes-stroke-treatment-time-587569
Viz.ai, a Tel Aviv-based start-up, is using FDA-approved artificial intelligence and deep learning technology to identify blood clots in the brain and alert stroke physicians within minutes. The companys platform has been proven to save time in stroke treatment, resulting in faster notification of specialists and improved patient outcomes. Viz.ai is backed by investors including Googles GV fund, Kleiner Perkins, and Innovation Endeavors. The company is now seeking to expand its technology to other healthcare scenarios, such as trauma and early detection of cancer.
Customers
growth-positive
Viz.ai Named Among Fast Company's Most Innovative Companies 2019
Viz.ai has been named one of the Worlds Most Innovative Companies by Fast Company. The company is recognized for its use of artificial intelligence in stroke care, improving patient access and speeding up clinical trials. Viz.ais stroke triage software is already being used by hundreds of US hospitals, allowing doctors to save critical time in the diagnosis and treatment of stroke. The software combines AI with seamless communication to facilitate the triage of stroke patients and collaboration between clinicians. Viz.ais synchronized care approach supports faster treatment, improved outcomes, and lower healthcare costs. The company plans to offer innovative tools for a broad range of diseases in the future. Viz.ai is backed by investors including Kleiner Perkins, Google Ventures, Innovation Endeavors, and DHVC.
CustomersInvestment
growth-positive
Viz.ai Named to the 2019 CB Insights AI 100 List of Most Innovative Artificial Intelligence Companies
Viz.ai, Inc. has been named to the CB Insights AI 100 ranking, which showcases the 100 most promising private artificial intelligence companies in the world. The selection was based on factors such as patent activity, investor quality, market potential, and team strength. Viz.ai is a leader in applied artificial intelligence in healthcare and offers a cloud-based AI system that analyzes medical images for potential large vessel occlusion strokes. The companys products aim to improve patient outcomes by enabling better collaboration between clinicians and speeding up the triage, diagnosis, and treatment of stroke patients. Viz.ai has experienced significant growth and has been recognized for its efforts in transforming healthcare through AI. The company is backed by investors such as Kleiner Perkins, Google Ventures, Innovation Endeavors, and DHVC.
PartnersInvestment
growth-positive
New Results from Viz.ai Research Demonstrate Ability to Automatically Detect Suspected Large-Vessel Occlusion Stroke in Non Contrast CT Head Scans
Viz.ai, Inc., an applied artificial intelligence company, has developed a novel method for the detection of signs of Large Vessel Occlusion Stroke (LVO) stroke in Non Contrast CT Head Scans (NCCT). The technology was independently assessed by researchers from Emory University. The ultimate goal of Viz.ai is to maximize the number of treated patients, minimize the time to treatment and improve the outcome of patients suffering stroke. Viz.ai is committed to developing novel technology to assist physicians in making faster decisions, and speed access to life saving treatment.
CustomersExpand
growth-positive
Viz.ai designated as American Heart Association/American Stroke Association Get With the Guidelines compatible vendor
Viz.ai has been designated as a compatible vendor for the American Heart Association/American Stroke Association Get With The Guidelines registry. This designation aims to improve quality metrics in stroke care by facilitating fast and accurate detection and referral of large vessel occlusion strokes. Viz.ais deep learning applied artificial intelligence and workflow software automatically detects and alerts stroke specialists about suspected large vessel occlusions. The companys technology enhances stroke teams capability to identify and triage potential strokes, leading to improved patient outcomes. Viz.ai is honored to be a compatible vendor that has demonstrated measurable patient outcome improvements.
PartnersCustomers
growth-positive
Viz.ai and NICO announce collaboration to speed patient recruitment in the ENRICH study
Viz.ai and NICO have collaborated to incorporate Viz.ais clinical trial recruitment software into the ENRICH study, which focuses on the treatment of intracerebral haemorrhages. The software, called Viz RECRUIT, uses artificial intelligence to identify potential subjects for clinical trials and notify investigators when a patient meets the eligibility criteria for enrolment. The collaboration aims to speed up the enrolment process and potentially shorten the clinical trial. ENRICH is a multicentre trial sponsored by NICO and led by the Emory Stroke Center and the Marcus Stroke & Neuroscience Center. The trial opened patient enrolment in January 2017.
PartnersCustomers
growth-positive
AI Diagnostics Startup Viz.ai Aims to Go Beyond Strokes
Stroke detection startup Viz.ai is expanding beyond strokes to other areas where quick diagnostic is key. The company develops an automated system that can analyze brain scans and alert stroke specialists. Viz.ais technology was cleared by the FDA. The company has received a total of $28.5 million in investment from GV and Innovation Endeavors.
InvestmentExpand
Viz.ai Awarded Best New Radiology Software
Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care
Viz.ai Raises $21 M in Series A Funding From Kleiner Perkins and GV to Increase Patient Access to Proven Therapies
growth-positive
Viz.ai Receives FDA Clearance for Automated Computed Tomography Perfusion (CTP) Software
Viz.ai, Inc. has received FDA clearance for its Viz CTP image processing software, which offers functional and dynamic CT perfusion image analysis. This clearance allows healthcare providers to have another tool for automated cerebral-image analysis. Viz.ai also offers other technology, including automated large vessel occlusion (LVO) stroke identification and patient selection. Stroke is a leading cause of disability and death, and Viz.ai aims to improve acute medical care through its artificial intelligence solutions. The company is financially backed by Innovation Endeavors and Danhua Capital.
PartnersInvestment
growth-positive
AI stroke treatment co Viz raises $7.5m
Viz, an AI company that uses AI to improve treatment of stroke victims, has completed a $7.5 million seed round from Innovation Endeavors and other investors. The companys solution instantly compares a patients scan to hundreds of thousands of other scans, helping doctors make quicker and more accurate decisions. Viz aims to dramatically shorten the time from when a patient asks for help until they receive suitable treatment. The funding round comes during the US National Stroke Awareness Month, highlighting the importance of efficient stroke treatment.
Investment
growth-positive
MedTech Startup Viz Diagnoses Strokes with Machine Learning
San Francisco-based MedTech startup Viz is using AI to diagnose strokes more quickly and effectively. The startup has received $2.5 million in backing from the investment firms of former Google exec Eric Schmidt and Yahoo founder Jerry Yang. Properly diagnosing and treating strokes is crucial as they often leave survivors with devastating after-effects. Vizs AI technology aims to provide ER doctors with the knowledge of top neuroscientists via machine learning, enabling them to identify strokes and provide better treatment. The startups innovative approach has the potential to save lives and reduce the strain on the American healthcare system, which currently faces a $74 billion burden due to unidentified or improperly treated strokes.
Investment
growth-positive
Tackling diagnostic medicine with AI, Viz launches a tool to identify strokes
San Francisco-based startup Viz, backed by Innovation Endeavors and AME Ventures, is using artificial intelligence to rapidly identify stroke victims and ensure faster treatment. The startup, founded by neurosurgeon Chris Mansi and David Golan, uses machine learning to identify anomalies in brain scans that even physicians have a hard time spotting. Viz aims to improve the diagnosis of neurological conditions, starting with strokes, which are the third leading cause of death in the US. The technology has attracted investment due to its potential to solve a significant problem in healthcare. Only three in every 100 stroke patients are currently being treated properly, leading to high healthcare costs and long-term disabilities.
Customers
Viz.ai Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 310 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Viz.ai Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 102/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515538049 |
| Crunchbase | viz |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-05T00:00:00.000Z |
| Created | 2017-05-15T00:00:00.000Z |